Carcinoma Specific CAR Construction Service

Are you currently facing challenges in developing effective CAR T cell therapies for solid tumors, struggling with antigen specificity, or overcoming the immunosuppressive tumor microenvironment? Our carcinoma-specific CAR construction service helps you accelerate drug discovery and obtain highly potent, precisely targeted CAR constructs through advanced genetic engineering and comprehensive validation.

Introduction

As a group of cancers, carcinoma usually starts from the skin and spreads to other organs of the body. It accounts for 90% of all cancers, which mostly occur in adults, with the DNA mutation as its main cause. Major subtypes include breast, prostate, colorectal, lung, cervical, melanoma, renal cell carcinoma, and adenocarcinomas. Common symptoms include lumps, skin discoloration, and pain. Although few strategies show effectiveness in carcinoma treatment, immunotherapy has shown great potential as a promising approach to treat carcinoma, such as CAR modified T cells or natural killer (NK) cells. Experts from Creative Biolabs can offer various CAR-T cell or NK cell construction services according to your request.

Fig.1 CAR-T cells can be engineered to trigger and enhance the endogenous tumor-specific immune response.¹

Carcinoma-Specific CAR Construction at Creative Biolabs

Creative Biolabs' carcinoma-specific CAR construction service provides a comprehensive, end-to-end solution for developing highly effective Chimeric Antigen Receptors tailored to the unique complexities of solid tumors. We deliver meticulously designed and validated CAR constructs, functional CAR-T cells, and detailed data analyses, empowering your preclinical and clinical advancements. Our solutions are specifically engineered to address critical challenges such as tumor antigen heterogeneity, the immunosuppressive tumor microenvironment, and T cell persistence, offering a pathway to more potent and safer immunotherapies for carcinoma.

As a leading and reliable service provider, Creative Biolabs is well known worldwide for its breakthroughs in the CAR production system. Based on targeting carcinoma-specific antigens, our outstanding scientists have constructed diverse CAR-T cells or CAR NK cells targeting these antigens. In addition to these, Creative Biolabs can also customize the CAR product according to your special requirements.

Service Process

Key Advantages

• Customized CAR Design and Construction: Tailored CAR constructs specifically engineered for your chosen carcinoma antigens and research objectives.
• Robust Viral Vector Production: High-titer, purified lentiviral or retroviral vectors ensuring efficient and safe gene delivery into T cells.
• High-Quality CAR-T Cell Manufacturing: Precise T-cell sorting, activation, and transduction protocols to generate functional CAR-T cells suitable for preclinical studies.

FAQs

Why Choose Us?

At Creative Biolabs, we are committed to accelerating your journey from scientific concept to therapeutic reality in carcinoma treatment. Our carcinoma-specific CAR construction service combines unparalleled scientific expertise with cutting-edge technology, delivering precise, potent, and safe CAR constructs designed to overcome the unique challenges of solid tumors. Partner with us to transform your research into groundbreaking cancer immunotherapies.

Customer Reviews

"The 4th-generation armored CARs constructed by Creative Biolabs have greatly facilitated our studies on T cell persistence in the harsh tumor microenvironment. We observed remarkably sustained anti-tumor activity, which was a significant improvement compared to our previous constructs." - 2025, Prof. JS Pr

"Creative Biolabs' comprehensive workflow, from scFv selection to final CAR-T cell validation, has streamlined our research process. Their detailed quality control and consistent deliverables have been invaluable in accelerating our preclinical development." - 2025, Dr. Sh Kr

How to Contact Us

Based on a great number of experiments, we are confident our first-class CAR products can greatly accelerate your project process. Please feel free to contact us at any time.

Products against Sarcoma-specific antigens

Reference

1. Wei, Jianshu et al. “Target selection for CAR-T therapy.” Journal of hematology & oncology vol. 12,1 62. 20 Jun. 2019, https://doi.org/10.1186/s13045-019-0758-x. Distributed under Open Access License CC BY 4.0, without modification.